3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Rhabdomyosarcoma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
pembrolizumab
259
Cyclophosphamide
244
Specimen Handling
197
fludarabine
175
Magnetic Resonance Spectroscopy
173
Biopsy
147
Nivolumab
122
Carboplatin
99
Radiotherapy
92
Paclitaxel
88
venetoclax
82
Cisplatin
82
fludarabine phosphate
79
Gemcitabine
79
Injections
69
Ipilimumab
64
Dexamethasone
62
atezolizumab
59
Cetuximab
58
Bevacizumab
58
Azacitidine
57
Radiation
56
Fluorouracil
56
durvalumab
54
Radiosurgery
53
Temozolomide
48
Rituximab
44
Oxaliplatin
44
Docetaxel
44
Irinotecan
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
1 year
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled